MedPath
Found 317 clinical trials|View Analysis
Sort by:

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

Phase 2
Recruiting
Conditions
Pancreatic Neoplasms
Neoplasm Metastasis
Hepatic Metastasis of Pancreatic Cancer
Interventions
Drug: Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin
Drug: Tegodor
First Posted Date
2024-08-06
Last Posted Date
2024-08-27
Lead Sponsor
Ruijin Hospital
Target Recruit Count
40
Registration Number
NCT06538623
Locations
🇨🇳

Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

Phase 2
Not yet recruiting
Conditions
Neoplasm Metastasis
Bevacizumab
Breast Neoplasms
Drug Therapy
Interventions
First Posted Date
2024-08-06
Last Posted Date
2024-08-06
Lead Sponsor
Wang Jiayu
Target Recruit Count
60
Registration Number
NCT06539559
Locations
🇨🇳

Beijing Chaoyang District San Huan Cancer Hospital, Beijing, Beijing, China

🇨🇳

Cancer Hospital of HuanXing ChaoYang District, Beijing, Beijing, China

🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Virtual Reality for Advanced Cancer Pain

Active, not recruiting
Conditions
Palliative Care
Neoplasm Metastasis
Pain
Interventions
Device: Virtual Reality
First Posted Date
2024-08-02
Last Posted Date
2024-12-06
Lead Sponsor
University College, London
Target Recruit Count
100
Registration Number
NCT06534580
Locations
🇬🇧

Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom

🇬🇧

Velindre University NHS Trust, Cardiff, United Kingdom

🇬🇧

Marie Curie Hospice, Liverpool, Liverpool, United Kingdom

and more 1 locations

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Phase 2
Recruiting
Conditions
Endometrial Neoplasms
Neoplasm Metastasis
Neoplasm Recurrence, Local
Interventions
First Posted Date
2024-08-01
Last Posted Date
2024-08-01
Lead Sponsor
Shandong Cancer Hospital and Institute
Target Recruit Count
30
Registration Number
NCT06532539
Locations
🇨🇳

Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Phase 1
Recruiting
Conditions
Neoplasm Metastasis
Interventions
Biological: MK-6837
Biological: Pembrolizumab
First Posted Date
2024-06-14
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
100
Registration Number
NCT06460961
Locations
🇨🇦

Princess Margaret Cancer Centre ( Site 2001), Toronto, Ontario, Canada

🇺🇸

Atlantic Health System Morristown Medical Center ( Site 4001), Morristown, New Jersey, United States

🇺🇸

Providence Portland Medical Center ( Site 4002), Portland, Oregon, United States

and more 3 locations

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Phase 1
Recruiting
Conditions
Neoplasm Metastasis
Interventions
Biological: Favezelimab/Pembrolizumab
Biological: Pembrolizumab
Biological: Pembrolizumab/Vibostolimab
Biological: Favezelimab
Biological: Vibostolimab
First Posted Date
2024-05-01
Last Posted Date
2024-12-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
80
Registration Number
NCT06395090
Locations
🇺🇸

Children's Mercy Hospital ( Site 2024), Kansas City, Missouri, United States

🇺🇸

Children's Hospital of Philadelphia (CHOP) ( Site 2021), Philadelphia, Pennsylvania, United States

🇨🇳

National Taiwan University Hospital ( Site 2983), Taipei, Taiwan

and more 7 locations

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Phase 3
Recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Interventions
First Posted Date
2023-11-07
Last Posted Date
2024-11-13
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1016
Registration Number
NCT06119581
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Highlands Oncology Group, Springdale, Arkansas, United States

🇦🇹

Ordensklinikum Linz GmbH Elisabethinen, Linz, Oberösterreich, Austria

and more 361 locations

Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study

Not Applicable
Withdrawn
Conditions
Breast Cancer
Triple Negative Breast Neoplasms
Neoplasm Metastasis
Inflammatory Breast Cancer Stage IV
Inflammatory Breast Neoplasms
Interventions
Behavioral: Self-Administered White Noise Hypnosis
Behavioral: Self-Administered Hypnosis
First Posted Date
2023-09-28
Last Posted Date
2024-05-10
Lead Sponsor
The University of Tennessee, Knoxville
Registration Number
NCT06057636
Locations
🇺🇸

University of Tennessee Knoxville, Knoxville, Tennessee, United States

Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.

Not Applicable
Recruiting
Conditions
Adenocarcinoma
Prostatic Neoplasm
Neoplasm Recurrence
Neoplasm Metastasis
Interventions
Other: Standard care
First Posted Date
2023-09-21
Last Posted Date
2023-09-21
Lead Sponsor
Centre Hospitalier Universitaire de Pointe-a-Pitre
Target Recruit Count
3000
Registration Number
NCT06046131
Locations
🇫🇷

CHU of Rennes, Rennes, Ille-et-Vilaine, France

🇬🇵

CHU of Guadeloupe, Pointe-à-Pitre, Guadeloupe

Clinical Application of Super-resolution Ultrasound(SR-US) Imaging in Solid Tumors

Recruiting
Conditions
Neoplasms, Liver
Neoplasm Metastasis
Ultrasound
Neoplasms Malignant
Microvessels
First Posted Date
2023-08-30
Last Posted Date
2023-08-30
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
100
Registration Number
NCT06018142
Locations
🇨🇳

Department of Interventional Ultrasound of Chinese PLAGH, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath